Primary composite endpoint at 12 months of serum alkaline phosphatase and bilirubin was met by 61.7% of patients treated with seladelpar 10 mg vs. 20.0% of placebo treated patients (p<0.0001) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback